Authentic neuroendocrine transdifferentiation from lung adenocarcinoma to small-cell lung cancer: a case report.
[BACKGROUND] Reports of small-cell lung cancer (SCLC) transdifferentiation in epidermal growth factor receptor tyrosine ()‑mutant lung adenocarcinoma (LUAD) often reflect pre‑existing combined SCLC or
APA
Li M, Zhou P, et al. (2026). Authentic neuroendocrine transdifferentiation from lung adenocarcinoma to small-cell lung cancer: a case report.. BMC pulmonary medicine, 26(1). https://doi.org/10.1186/s12890-026-04180-8
MLA
Li M, et al.. "Authentic neuroendocrine transdifferentiation from lung adenocarcinoma to small-cell lung cancer: a case report.." BMC pulmonary medicine, vol. 26, no. 1, 2026.
PMID
41820948
Abstract
[BACKGROUND] Reports of small-cell lung cancer (SCLC) transdifferentiation in epidermal growth factor receptor tyrosine ()‑mutant lung adenocarcinoma (LUAD) often reflect pre‑existing combined SCLC or are limited by sampling bias, obscuring true treatment‑induced lineage transformation.
[CASE PRESENTATION] We report a female patient with EGFR‑mutant LUAD who, during tyrosine kinase inhibitor therapy, developed SCLC transformation confirmed histopathologically. The patient showed limited response to first‑line SCLC chemoimmunotherapy, and a subsequent biopsy revealed mixed SCLC/LUAD histology with neuroendocrine differentiation and shared genetic alterations between components.
[CONCLUSIONS] This case provides strong clinicopathological and molecular evidence supporting neuroendocrine transdifferentiation from LUAD to SCLC, culminating in a mixed phenotypic state. Further research is needed to define optimal therapeutic strategies for this resistant phenotype.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12890-026-04180-8.
[CASE PRESENTATION] We report a female patient with EGFR‑mutant LUAD who, during tyrosine kinase inhibitor therapy, developed SCLC transformation confirmed histopathologically. The patient showed limited response to first‑line SCLC chemoimmunotherapy, and a subsequent biopsy revealed mixed SCLC/LUAD histology with neuroendocrine differentiation and shared genetic alterations between components.
[CONCLUSIONS] This case provides strong clinicopathological and molecular evidence supporting neuroendocrine transdifferentiation from LUAD to SCLC, culminating in a mixed phenotypic state. Further research is needed to define optimal therapeutic strategies for this resistant phenotype.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12890-026-04180-8.
같은 제1저자의 인용 많은 논문 (5)
- Icariside II suppresses NF-κB/STAT3 signaling to prevent the progression of chronic atrophic gastritis toward gastric cancer.
- The protective role of a moderate protein diet in ETEC-infected piglets: Optimization of growth, immunity, and microbial balance.
- STOML2 promotes hepatocellular carcinoma cell proliferation, invasion and migration by activating the PI3K/AKT signaling pathway (Review).
- Kinesin Family Member 26A Disrupts DNA-Dependent Protein Kinase Complex Formation to Enhance Chemoradiotherapy Sensitivity in Colorectal Cancer.
- Developing an automatic decision-assistance tool to choose proton/photon radiotherapy for patients with prostate cancer.